Virbac, one of the world’s leading companies in animal health, is continuing its expansion in Europe.
In addition to the recent finalization of the creation of its Irish subsidiary, Virbac announces the acquisition of its historical distributor in the Czech Republic and Slovakia, which becomes its 35th subsidiary.
This development strategy strengthens the group’s position in the European market for animal health.
Present in the Czech Republic and Slovakia since 2000 through its historical distributor, Virbac is well aware of these two markets, mainly oriented towards pets and ruminants.
In order to continue the development of its activities in this region and strengthen its presence in Central Europe, Virbac has acquired GS Partners, one of its oldest distributors in this area. This acquisition crowns the excellent work done for years by the teams of Jakub Satrapa, its former owner and future CEO of the Virbac subsidiary.
The new Virbac subsidiary in Ireland and the acquisition of GS Partners in the Czech Republic and Slovakia will allow the group to respond more broadly and quickly to the health needs of animals in these countries. Therefore, this development strategy strengthens Virbac’s position in the European animal health market, where the group continues to grow and expand.
Healthtech & Biotech News – Nice Côte d’Azur France
- Obesity: French first at Nice University Hospital
- Team Nice Côte d’Azur at the Van Lanschot Kempen Life Sciences Conference 2026
- Launch of the AZUR Territorial Research Entity to advance clinical research on the French Riviera
- BIO-Europe Spring 2026 : meet with Team Nice Côte d’Azur
- Eurobiomed: more than €300 million secured in 2025 in the Sud and Occitanie regions by Eurobiomed member healthcare companies
- Artificial intelligence: Team Nice Côte d’Azur mobilized for an AI Business Tour and WAICF 2026
- Nice University Hospital signs an international cooperation agreement with Emirates Hospitals Group (Dubai)
- Caranx Medical, a Nice-based cardiac robotics MedTech startup, set to be acquired for €16.6 million
- AVC continues its expansion with a consolidated base in the Côte d’Azur
- New medical governance at CHU de Nice
